Moderna's first-quarter vaccine sales more than tripled over the same period last year, when it reported $1.7 billion in sales.
The biotech company reported $3.66 billion in net income for the quarter, a threefold increase over the $1.2 billion it reported in the same period last year.The Moderna Covid-19 vaccine awaits administration at a vaccination clinic in Los Angeles, California on December 15, 2021.sold $5.9 billion of its Covid vaccine in the first quarter, blowing out revenue and profit expectations.The biotech company on Wednesday maintained its full-year guidance of $21 billion in Covid vaccine sales.
Moderna's first-quarter vaccine sales more than tripled over the same period last year, when it reported $1.7 billion in sales shortly after the shots first rolled out. The Covid vaccine, Spikevax, is the biotech company's only commercially available product. Here's how Moderna performed compared with what Wall Street expected, based on analysts' average estimates compiled by Refinitiv:: $6.07 billion, vs. $4.62 billion expected
Moderna reported $3.66 billion in net income for the quarter, a threefold increase over the $1.2 billion it reported in the same period last year.